FI72648B - Foerfarande foer framstaellning av fasta, laett resorberande och laongtidsverkande laekemedelspreparat innehaollande nifedipin. - Google Patents
Foerfarande foer framstaellning av fasta, laett resorberande och laongtidsverkande laekemedelspreparat innehaollande nifedipin. Download PDFInfo
- Publication number
- FI72648B FI72648B FI812758A FI812758A FI72648B FI 72648 B FI72648 B FI 72648B FI 812758 A FI812758 A FI 812758A FI 812758 A FI812758 A FI 812758A FI 72648 B FI72648 B FI 72648B
- Authority
- FI
- Finland
- Prior art keywords
- nifedipine
- och
- surface area
- crystals
- specific surface
- Prior art date
Links
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 30
- 229960001597 nifedipine Drugs 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000013078 crystal Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- OSUCQKNXQBPLDG-UHFFFAOYSA-N 2,6-dimethyl-4-(2-nitrophenyl)-3,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester Chemical compound COC(=O)C1=C(C)N=C(C)C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O OSUCQKNXQBPLDG-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 230000036211 photosensitivity Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 238000004438 BET method Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000021551 crystal sugar Nutrition 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI893544A FI893544A7 (fi) | 1980-09-09 | 1981-09-07 | Spesifisten nifedipiinikiteiden käyttö kiinteiden, helposti imeytyvien ja pitkävaikutteisten lääkevalmisteiden valmistukseen |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3033919 | 1980-09-09 | ||
| DE19803033919 DE3033919A1 (de) | 1980-09-09 | 1980-09-09 | Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI812758L FI812758L (fi) | 1982-03-10 |
| FI72648B true FI72648B (fi) | 1987-03-31 |
Family
ID=6111496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI812758A FI72648B (fi) | 1980-09-09 | 1981-09-07 | Foerfarande foer framstaellning av fasta, laett resorberande och laongtidsverkande laekemedelspreparat innehaollande nifedipin. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0047899B2 (fa) |
| JP (1) | JPS5914446B2 (fa) |
| AR (1) | AR226377A1 (fa) |
| AT (1) | ATE5761T1 (fa) |
| AU (1) | AU558331B2 (fa) |
| CA (1) | CA1180277A (fa) |
| DD (1) | DD201974A5 (fa) |
| DE (2) | DE3033919A1 (fa) |
| DK (1) | DK154326C (fa) |
| FI (1) | FI72648B (fa) |
| GR (1) | GR78237B (fa) |
| HU (1) | HU184879B (fa) |
| IE (1) | IE51549B1 (fa) |
| IL (1) | IL63749A (fa) |
| NO (1) | NO157368B (fa) |
| NZ (1) | NZ198285A (fa) |
| PH (1) | PH24097A (fa) |
| PL (1) | PL232951A1 (fa) |
| PT (1) | PT73603B (fa) |
| ZA (1) | ZA816213B (fa) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5264446A (en) * | 1980-09-09 | 1993-11-23 | Bayer Aktiengesellschaft | Solid medicament formulations containing nifedipine, and processes for their preparation |
| JPS5846019A (ja) * | 1981-09-14 | 1983-03-17 | Kanebo Ltd | 持続性ニフエジピン製剤 |
| DE3222367A1 (de) * | 1982-06-15 | 1983-12-15 | Bayer Ag, 5090 Leverkusen | Verwendung von 1,4-dihydropyridinen in antiarteriosklerotika und deren herstellung |
| JPS59101423A (ja) * | 1982-12-02 | 1984-06-12 | Takada Seiyaku Kk | 新規なニフエジピン固形製剤 |
| US4529733A (en) * | 1983-04-06 | 1985-07-16 | Merrell Dow Pharmaceuticals Inc. | Antihypertensive 3-furoyl-1,4-dihydropyridines |
| DE3318649A1 (de) * | 1983-05-21 | 1984-11-22 | Bayer Ag, 5090 Leverkusen | Zweiphasenformulierung |
| HU198844B (en) * | 1984-06-14 | 1989-12-28 | Sandoz Ag | Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient |
| IT1178511B (it) * | 1984-09-14 | 1987-09-09 | Pharmatec Spa | Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio |
| IT1187751B (it) * | 1985-10-15 | 1987-12-23 | Eurand Spa | Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute |
| US5198226A (en) * | 1986-01-30 | 1993-03-30 | Syntex (U.S.A.) Inc. | Long acting nicardipine hydrochloride formulation |
| US4940556A (en) * | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
| CH673947A5 (fa) * | 1986-09-23 | 1990-04-30 | Sandoz Ag | |
| JPS6464659A (en) * | 1987-09-03 | 1989-03-10 | Kenbi Kogaku Kenkyusho Kk | Preparation of safe and effective powder formulation |
| SE8703881D0 (sv) * | 1987-10-08 | 1987-10-08 | Haessle Ab | New pharmaceutical preparation |
| DE3814532A1 (de) * | 1988-04-29 | 1989-11-09 | Bayer Ag | Dhp-retard-zubereitung |
| JPH0298550U (fa) * | 1989-01-25 | 1990-08-06 | ||
| GB8903328D0 (en) * | 1989-02-14 | 1989-04-05 | Ethical Pharma Ltd | Nifedipine-containing pharmaceutical compositions and process for the preparation thereof |
| US5271944A (en) * | 1991-04-05 | 1993-12-21 | Biofor, Ltd. | Pharmacologically enhanced formulations |
| DE4130173A1 (de) * | 1991-09-11 | 1993-03-18 | Bayer Ag | Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters |
| GB9200607D0 (en) * | 1992-01-13 | 1992-03-11 | Ethical Pharma Ltd | Pharmaceutical compositions containing nifedipine and process for the preparation thereof |
| US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| US6726930B1 (en) | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5543099A (en) * | 1994-09-29 | 1996-08-06 | Hallmark Pharmaceutical, Inc. | Process to manufacture micronized nifedipine granules for sustained release medicaments |
| ES2168351T3 (es) * | 1994-12-29 | 2002-06-16 | Shire Deutschland Gmbh & Co Kg | Preparaciones farmaceuticas que contienen nifedipina y procedimiento para su preparacion. |
| JP3220373B2 (ja) | 1995-11-28 | 2001-10-22 | バイエル薬品株式会社 | 持続性ニフエジピン製剤 |
| AU695734B2 (en) | 1996-07-08 | 1998-08-20 | Penwest Pharmaceuticals Co. | Sustained release matrix for high-dose insoluble drugs |
| IT1284604B1 (it) * | 1996-09-27 | 1998-05-21 | Roberto Valducci | Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva |
| US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| DE60038536T2 (de) | 1999-09-30 | 2009-06-10 | Penwest Pharmaceuticals Co. | Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe |
| MX2007000911A (es) | 2004-07-30 | 2007-04-12 | Torrent Pharmaceuticals Ltd | Nevibolol y sus sales farmaceuticamente aceptables, proceso para su preparacion y composiciones farmaceuticas de nevibolol. |
| DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3330727A (en) * | 1960-04-19 | 1967-07-11 | Glaxo Lab Ltd | Griseofulvin with high specific surface area |
| US3401221A (en) * | 1964-08-25 | 1968-09-10 | Norwich Pharma Co | Treatment of urinary tract infection |
| DE2348334C2 (de) * | 1973-09-26 | 1982-11-11 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs |
| DE2400819C2 (de) * | 1974-01-09 | 1982-04-22 | Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung |
| GB1579818A (en) * | 1977-06-07 | 1980-11-26 | Yamanouchi Pharma Co Ltd | Nifedipine-containing solid preparation composition |
| JPS55129221A (en) * | 1979-03-29 | 1980-10-06 | Kaken Pharmaceut Co Ltd | Preparation of oral preparation containing hardly soluble medicine |
| CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
-
1980
- 1980-09-09 DE DE19803033919 patent/DE3033919A1/de not_active Ceased
- 1980-12-27 JP JP55185148A patent/JPS5914446B2/ja not_active Expired
-
1981
- 1981-08-25 NO NO812879A patent/NO157368B/no unknown
- 1981-08-28 DE DE8181106729T patent/DE3161838D1/de not_active Expired
- 1981-08-28 EP EP81106729A patent/EP0047899B2/de not_active Expired - Lifetime
- 1981-08-28 AT AT81106729T patent/ATE5761T1/de not_active IP Right Cessation
- 1981-08-31 PH PH26121A patent/PH24097A/en unknown
- 1981-08-31 PT PT73603A patent/PT73603B/pt unknown
- 1981-09-01 DD DD81232939A patent/DD201974A5/de not_active IP Right Cessation
- 1981-09-07 NZ NZ198285A patent/NZ198285A/en unknown
- 1981-09-07 FI FI812758A patent/FI72648B/fi not_active Application Discontinuation
- 1981-09-07 GR GR65968A patent/GR78237B/el unknown
- 1981-09-07 IL IL63749A patent/IL63749A/xx not_active IP Right Cessation
- 1981-09-08 ZA ZA816213A patent/ZA816213B/xx unknown
- 1981-09-08 IE IE2075/81A patent/IE51549B1/en not_active IP Right Cessation
- 1981-09-08 CA CA000385365A patent/CA1180277A/en not_active Expired
- 1981-09-08 PL PL23295181A patent/PL232951A1/xx unknown
- 1981-09-08 AR AR286686A patent/AR226377A1/es active
- 1981-09-08 DK DK396381A patent/DK154326C/da not_active IP Right Cessation
- 1981-09-08 AU AU75063/81A patent/AU558331B2/en not_active Expired
- 1981-09-09 HU HU812594A patent/HU184879B/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5750913A (en) | 1982-03-25 |
| DD201974A5 (de) | 1983-08-24 |
| ZA816213B (en) | 1982-09-29 |
| AU7506381A (en) | 1982-03-18 |
| IE51549B1 (en) | 1987-01-07 |
| PH24097A (en) | 1990-03-05 |
| HU184879B (en) | 1984-10-29 |
| EP0047899B2 (de) | 1996-02-28 |
| ATE5761T1 (de) | 1984-01-15 |
| EP0047899A1 (de) | 1982-03-24 |
| GR78237B (fa) | 1984-09-26 |
| IL63749A0 (en) | 1981-12-31 |
| FI812758L (fi) | 1982-03-10 |
| AU558331B2 (en) | 1987-01-29 |
| DE3161838D1 (en) | 1984-02-09 |
| PT73603A (en) | 1981-09-01 |
| DK396381A (da) | 1982-03-10 |
| IE812075L (en) | 1982-03-09 |
| DE3033919A1 (de) | 1982-04-22 |
| NO812879L (no) | 1982-03-10 |
| JPS5914446B2 (ja) | 1984-04-04 |
| EP0047899B1 (de) | 1984-01-04 |
| CA1180277A (en) | 1985-01-02 |
| IL63749A (en) | 1984-06-29 |
| PT73603B (en) | 1982-11-10 |
| DK154326C (da) | 1995-03-13 |
| PL232951A1 (fa) | 1982-10-11 |
| NZ198285A (en) | 1984-04-27 |
| DK154326B (da) | 1988-11-07 |
| AR226377A1 (es) | 1982-06-30 |
| NO157368B (no) | 1987-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI72648B (fi) | Foerfarande foer framstaellning av fasta, laett resorberande och laongtidsverkande laekemedelspreparat innehaollande nifedipin. | |
| US5264446A (en) | Solid medicament formulations containing nifedipine, and processes for their preparation | |
| FI82376C (fi) | Foerfarande foer framstaellning av tvaofasiga, fasta laekemedelspreparat. | |
| FI117888B (fi) | Mikrojauhettua nebivololia sisältäviä koostumuksia | |
| KR100353304B1 (ko) | 맛이 차폐된 마이크로캡슐 조성물 및 이것의 제조 방법 | |
| RU1816213C (ru) | Способ получени твердой лекарственной формы с регулируемым выделением лекарственного средства | |
| FI116773B (fi) | Menetelmä mykofenolaattimofetiilin oraalisten suurannossuspensioiden valmistamiseksi | |
| JP2740993B2 (ja) | 内服用新規医薬製剤 | |
| DE3783332T2 (de) | Spruehgetrocknetes acetaminophen. | |
| JP2918691B2 (ja) | ラニチジン組成物 | |
| AU642747B2 (en) | Antimalarial compositions | |
| JPH0737384B2 (ja) | 経口投与用調合剤 | |
| CA1298199C (en) | Spray dried acetaminophen | |
| EP2854773B1 (en) | Pharmaceutical composition of entecavir and process of manufacturing | |
| DE69934781T2 (de) | Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen | |
| JP5504312B2 (ja) | 薄層糖衣錠およびその製造方法 | |
| HUE033525T2 (en) | Pharmaceuticals containing Etoricoxib | |
| EP1929997A1 (en) | Oxcarbazepine formulations | |
| RU96100835A (ru) | Способ получения флавано-лигнановых композиций с улучшенными высвобождением и всасываемостью, композиции, получаемые этим способом, содержащее их лекарственное средство и способ его получения | |
| EP0538034B1 (en) | Taste mask coatings for preparing chewable pharmaceutical tablets | |
| EP0473431A1 (en) | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | |
| KR100281521B1 (ko) | 프라바스타틴나트륨이 함유된 약제 조성물 | |
| EP1707192A2 (en) | Pharmaceutical composition | |
| Chowdary et al. | Controlled release of nifedipine from mucoadhesive tablets of its inclusion complexes with β-cyclodextrin | |
| JPH05194233A (ja) | マイクロペレットおよびそれらの製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |
Owner name: BAYER AKTIENGESELLSCHAFT |